All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The transforming growth factor β (TGF-β) signaling is responsible for the functional inhibition of mesenchymal stromal cells and suppression hematopoietic progenitor cells in MDS and AML. TGF-β pharmacologic blockage, with drugs like luspatercept or sotatercept, can reverse that suppression and promote late-stage erythropoiesis.